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R U 38882 is a new antiandrogen . When given by subcu-
taneous or o ral route, R U 38882 is about 25 times less 
potent than cyproterone ace tate. H owever, w hen applied 
topicall y to the intact rat skin, RU 38882 (0.25-25 mg/rat/day 
fo r 5 days o r 3 weeks) decreases, in a dose-related m an ner, 
the vo lume density of the sm ooth endoplasmic reticulum 
vesicles of th e differentiating ce ll s of the sebaceous gland , 
a stru cture directl y involved in sebum lipid synthes is. Un-
A ndrogens are in volved in the regulation of the hol-ocrin e functi o n o f the sebaceous g land in va ri ous ani m al species, and in th e human, sebum production is also under androgen control [1 ,2]. Smce hypcrseb-o rrhea is one o f the prim ary fea tures in the devel-
opment of acne, antiand rogens have been used with so me success 
to treat hypersebo rrhea and acne [3- 6], the most act tve bemg 
cyprote rone ace tate w hi ch ei ther alon e o r given as a contraceptive 
pi ll (D iane), inhibi ts se bum excretton rate by up ro 50% [7,8] 
and improves acne [8,9]. H owever untd now these drugs have 
been effe cti ve main ly w hen given b y the o ral route (cyp roterone 
acetate is inacti ve on to pical app li ca tion [1 0]) and for o bvio us 
reaso ns ca nn o t be ad ministered to male patients. Consequentl y, 
an antiandrogen active w hen appli ed to th e skin , but w ithout 
systemic antiand rogenic activity especiall y o n sexual organs, would 
be a very useful potenti al dru g for the trea tm ent of androgen-
dependent skin disorders such as hypersebo rrhea, acne , hirsutism, 
an d ma le-pattern ba ldness. 
In thi s paper we describe a new antiandrogen, R U 38882, which 
w hen applied topi ca ll y to rat sk in exhibits marked antiandrogcnic 
ac tivity o n the sebaceous gland but not o n the prostate . 
MATE RIALS AND METHODS 
Compounds R U 38882 ([3S-(3a,3aa, 9aa , %{3)]-3-(ace tyloxy)-
6 - eth yl- 3a -methyl-1 , 2, 3, 3a , 4, 5, 8, 9, 9a, 9b- decahydro- 7H-
benz(e]inden-7-onc) was iss ued from a joint research prog ram 
between Roussel-Uclaf Research Center and College de France 
(Paris) [11 , 12]. Cypro tero ne acetate was ex tracted from Androcur 
(France). [3H)Meth yltrienolo ne (sp act 50 C i/ mmol) was sy nthe-
tized at the Rousscl-UclafR esca rch Center and checked for purity 
(>95%) before usc. 
Animals and Treatments 
Subcutaneo 11s and O ral A dministration: G roups ofS immature male 
rats (Sprague-Dawlcy, 70-80 g, c:tstratcd 24 h previous ly) re-
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der these conditions RU 38882 is about 100 times more 
potent than cy proterone acetate and unlike cyproterone 
acetate, does not modify the prostate weight. The lack of 
efficacy of cyproterone acetate on the sebaceous gland could 
be due to its partial androgenic acti vity w hile RU 38882, 
under these conditions, acts as a pure antiandrogen w hich 
inhibits the nuclea r androgen-receptor translocation . J In-
vest Dennatol 86:163-167, 1986 
ccived for 7 days, dail y treatments w ith var io us doses of RU 
38882 o r cy pro terone acetate administered either s.c . in 0.1 ml o f 
sa line cont:1inin g 0.2% Tween o r o rall y in 0.4 ml of water con-
taining 0.25% of ca rboxymeth yl cellulose and 0.2% Tween. These 
treatments were g iven either alo ne or in combination w ith 50 }.Lg 
of testos tero ne pro pionate administered s.c. in 0 .1 ml of saline 
contai nin g 0.2% Tween. Contro ls received solvent on ly. Rats 
we re sacrificed 24 h after the last trea tm ent. T he pros tates were 
rem oved and weighed. 
T opical Adlllillislration: G ro ups of 5 ad ult male rats (Sprague-
Dawley. 200 g, intact o r cas trated 4 weeks previously) were shaved 
in the intcrscapul ary area. Twenty-four hours later, various doses 
(0.05, 0.5, and 5 mg/cm2/ day) ofRU 38882 or cy proterone ace tate 
disso lved in 100 J.Ll of pure ethan o l, were applied dail y to a 
S-cm ~ area of shaved sk in , alone (i nta ct rats) o r simultaneously 
w nh 0. 250 tng o f tes tostero ne propio nate administered s. c. (cas-
trated rats) either fo r 5 days, or fo r 3 consecuti ve weeks (intact 
rats). Controls received solvent on ly. The animals were sacrifi ced 
24 h afte r the last treatment. Frag m ents of treated skin were 
rem oved for hi sto logic exa minati on and determ ination of andro-
gen rece ptor concentrati on . Prostates were excised and weighed . 
Histologic Techniques and Stereologic Analysis Skin bio p-
stes we re treated as previously described (1 3]. B ri efl y, skin biop-
sies were immediately fixed by immersio n in 4% g lutara ldehyde 
buffered to pH 7.3 (4°C) in 0. 1 M phosphate saline buffer. The 
specimens were rinsed in the buffer, cut into small fragments, 
postfi xed fo r 1 h in phosphate sa line-buffered 1% osmium te-
trox ide (pH 7.4, 4°C), dehyd rated throu gh a g raded series of 
ethano l, and embedded in Epon 812. Blocks were cut w ith glass 
o r d iamond kni ves. Sectio ns 1 JLm thi ck were mo unted o n glass 
slides and stained with 0.5% toluidine blue in sodium borate for 
li ght-microscopic exa mina tion and foca liza tion of the sebaceous 
g lands. U ltrathin sections were mounted on coated g rid s, stained 
w ith uranyl ace tate, and th en by lead citrate for exa mination w ith 
an electro n microsco pe (E lmisko p 101 Siemens) at 80 kV. 
Stcrcolog ir A nalysis: In all gro ups 2 se baceous glands were ran-
do ml y chosen fro m each rat and the diffen:ntiating cells were 
exam ined. T he photogra phic field s were selected from the peri-
nuclear area of these di ffe rentiating cell s. Stereo logic analysis was 
ca rried o ut on at leas t 10 mi crographs for each gland at a fi nal 
magnifi ca tio n of x 50,000 to eva luate the vo lume density of th e 
smooth-membrane vesicles. Fo r each mi crog raph , a coherent 
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Table I. Effect of Subcutaneous Injections of 
RU 38882 and Cyproterone Acetate on the 
Immature Castrated Rat Prostate Wei ght 
Dose Pros tate Weight 
(mg/day/rat) (mg ± SEM) 
Control 19.9 ± 0.7 
RU 38882 0.2 19.0 ± 13 (-)" 
1 19.8 ± 1.4 (-) 
5 19.7 ± 1.3 (-) 
Cyp rotero ne 0.04 20.5 ± 1.7 (-) 
ace tate 0.2 2 1. 3 ± 1.7 (-) 
I 22.3 ± 3.3 (-) 
Com po unds we re ad ministered S. C., dail y ror 7 days, (Q immatllrl.' cast r~ncd rats, 
as d escribed und er /\1M crials 1111(/ Methods. 
' ( - ). Not significantly different from the control. 
multipurpose test syste m [14] containin g 100 points was used and 
was randomly placed over the cyto plas mic areas devoid of lipid 
droplets . A line, 9 mm in length (cal ibration d = 0.9 em) , was 
chosen because the diameter of the vesicles docs not exceed that 
length. The volume density (Vv) of the vesicular endo plasmic 
reticulum was calculated from the eq uation , Vv = Pi/ PT, in 
which Pi is the number of points falling within the limits of the 
vesicles and PT is the total number of points lying within the 
sebaceous cell cy to pl as m. 
Stalislical Analysis: The res ults were given as a mea n ± SEM 
and statistica l comparisons of data were performed by the Dunnett 
test. Differences with p < 0.01 were considered sta tist icall y sig-
nificant. 
Measurement of Androgen Receptor Concentration Skin 
fragments of ad ult rats were freed of epidermis by scraping. Ti s-
sue (mainly dermis) was min ced with scissors, pul verized in liquid 
nitrogen, and then ·ho mogenized (0-4°C) with a TeAon-glass ho-
mogenize r in 2 vol (w/v) of Tris buffer (10 mM Tris- H C l (pH 
7.4), 0.25 mM sucrose, 2 mM dithiothreito l, and 0.1 mM phen-
ylmethylsulfony l Auoride. T he homogenates were centrifuged at 
105,000 g fo r 60 min (0-4°C) in a Spinco Beckmann ultra centri-
fuge (rotor Ti 50). The supernatant (cytosol) was freed of en-
dogenous ho rm o nes by treatment with a charcoal suspension 
(charcoal N orit A, 6.25%-Dex tran 80,000, 3. 125%) and then 
centrifuged at 800 ,!? for 10 min. Cy tosoli c androgen recepto r 
concentration was measured in the supernatant by an exchange 
assay using (31-l]methyltrieno lone and a 100-fold excess of triam-
cinolone aceton ide as previously described [1 5}. Androgen re-
cepto r concentration was calcu lated by Scatchard analysis I 16]. 
Serum Testosterone Assay Plasma testosterone levels were 
determined by radioimmunoassay as previously described l1 7] 
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Figure 1. Antiandrogenic activity ofRU 38882in the castrated immature 
rat. !\nimals were treated as described under Materials a11d Methods: (A) 
by the subcutaneous ro ute, (B) by the o ral route. 
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Figure 2. Electron microg raphs of the differcmiating cel ls of the rat 
sebaceous gland . A , Intact ad ult rat. B. Intact adult rat w hich has recei ved 
dai ly topi cal application (2.5 m g/ rat) for 5 days of RU 388!:l2 (see Materials 
all(/ Methods). 11 = Nucleus; 111 = mitocho ndrion; I = li pid dro plet; arro111s 
indica te ves icles of smooth endoplasmic reti culum . 
using an antibody produced by immuniza tion of rabbits with 
testosteronc-11-hemisuccinatc coupled w ith bovine serum albu-
min (Roussel-Uclaf). The cross-reac ti vity of this antibody wa 
very low. T he sensitivity o f th e assay was 10 pg and the coeffi cient 
o f va riation abo ut 10% . 
RES ULTS 
Effect of Subcutaneous and Oral Administration on the 
Prostate Weight of the ln'lmature Castrated Rat Wh en in-
jected s. c., neither H U 38882 no r cy pro terone acetate increases 
the prostate weig ht of the cas trated rat (Ta ble 1). T hus, un der 
these conditions, and at the doses used, RU 38882, like cypro-
terone aceta te, docs not ex hibit any androgenic activity . How-
eve r, at the sa me doses , the y prevent in a dose-related m anner 
th e incrca c in prostate weight tri ggered by a simultaneous .c. 
inj ection of 50 J.L g of testosterone pro pionate. A dai ly s.c. dose 
of 5 m g/ rat of RU 38882 leads to a 50% inhibition (Fig l A). 
Under these conditions RU 38882 is a weak antiandrogen, about 
25 times less active than cyp ro teron e acetate . By the o ral route 
(Fig 1B), RU 38882 is about 25 times less po tent than by the s.c . 
route. 
Effect of Topical Application to the Rat Skin After topi cal 
appli ca ti on o f the compounds ro rat skin, both loca l and sys temic 
antiandrogenic effects were investiga ted. Loca l effects were eval-
uated: (1) by histo logic modifi cations of the sebaceous gland; and 
(2) by the modifi cation s of androgen receptor concentration in 
the derm is, w hile sys temi c effects were app reciated by changes 
in prostate weight. 
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Table II. EtTect of Topic:.ll Applica tions of RU 38882 to the Skin of Testosterone-T reated Castrated R ats 
Dose 
(mg/ day/ rat) 
Con trol 
(4 wk cas trated) 
0.250 Tes tosterone 
propiona te (s.c.) 
TP + RU 38882 0.25 2.5 
25 
Qp < 0.0 1 compared w ith the testos tero ne propionate group . 
;(- ), Not significantl y different fro m th e TP group. 
No. of 
Animals 
5 
5 
5 
5 
5 
In th e sebaceous g land sebum lipids are synthetized in the dif-
fe rentiatin g cells by the sm ooth end op las mic reticulum (SER). 
Under electron-microscopic examination of these cell s, SER ap-
pears as sma ll vesicles located in th e cy to plas m (Fig 2A). In the 
rat sebaceous g land , we have prev io usly shown [1 3] that the 
volum e density of these vesicles is under androgen con tro l: it is 
decreased b y cast rat io n and is restored to con tro l level after tes-
tostero ne propionate inj ectio n . T hus the effect of the rest com-
pounds on the sebaceous g land was eva luated by their ability to 
modify the vo lume density of these SER ves icl es. Expenmenrs 
were performed in the intact as well as in the castrated rat. 
Effect on the Testostero11e- Treated Castrated Rat a11d the l11tact Rat: RU 
38882 applied top ica ll y for 5 days to the skm of testosterone 
propionate-treated cast rated rats, prevents, in a dose-re lated m an-
ner, th e increase in the volume density of SER ves icles, triggered 
by testos tero ne propionate alon e (Table II) . O n the co ntrary, no 
significant decrease in prostate weig ht cou ld be obser ved . 
In the sa m e way, daily topica l appli ca tions (for 5 days) of R U 
38882 to the skin of intact rats, result, like castra tion, in a marked 
decrease in rhe vo lume density of SER ves icles of the differen-
tiating cells of the sebaceous g land (Figs 2B, 3A). This effect is 
dose- re lated and a 30% inhibition is observed fo llowing ap pli-
cation of a dose as low as 0.05 m g/cm 2/day (0.25 mg/rat/ da y). 
A daily dose of 0.50 m g/cm 2 (2 .5 m g/rat) is nearly as effective 
as castratio n . On the co ntrary , cyprotero ne acetate has no sig-
nificant effect, a s lig ht decrease in the volume density of SER 
vesicles bein g observed at the hi g hest dose (5 m g/c m 2/day, i.e., 
25 mg/rat/day) o nl y. Under these conditi o ns cyprotero ne acetate 
is at leas t 100 times less potent than R U 38882. 
Like castration, daily topi ca l ap pli ca tion of RU 38882 trigge rs 
an in creased recovery in cytoso li c androgen recepto r (A R) con-
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Figure 3. Effect of topica l app lica tion (for 5 days) of RU 38882 and 
cyproterone ace tate (Cyp. A c.) to intact rat skin, (A) on the volume density 
of SER ves icles in the differentiating cells of the sebaceous gland, and (B) 
on prostate weight. C = Control (intact rats). 
Volume Density 
of SER Vesicles 
(X 10-' ± SEM) 
9 ::!:: I 
76 ::!:: 6 
43 ::!:: 5'' 
22 ::!:: 3'' 
14 ± 3" 
Prostate Weight 
(mg::!:: SEM) 
28 ::!:: 3 
11 5 ::!:: 14 
99::!:: 10 (-)1' 
99::!::22(-) 
104 ::!:: IS(-) 
centration in the treated-rat dermis (Fig 4) . T his increase is dose-
related , and m axim al (similar to that observed after castratio n) at 
daily doses th at marked ly decrease the volume density of SER 
vesicles in the sebaceous g !Jnd (0.5 and 5 m g / cm2 , i.e., 2.5 and 
25 m g/rat) . O n the contrary, dai ly topi ca l application of cypro-
tero ne acetate triggers a dose-re lated decrease in cytosoli c AR 
concentrati o n and at the hig hest dai ly dose (5 m g /cm2 , i. e., 25 
mg/ rat) leads, like tes tosterone, to a disappearance of AR from 
the cytoso lic fraction (Fig 4). T hese modificatio ns can not be at-
tributed to masking of the androgen binding sires by rhe rest 
compound since AR concentration was measured usin g an ex-
change assay , nor to va riations in serum testos terone levels w hi ch 
were nonsignificantly sli g htl y increased (controls 5 ± 3 ng/ ml ; 
treated 8 ± 5 ng/ ml) . 
Under these conditions , no modifi ca tion of prostate weig ht is 
observed after topica l app li ca ti o n of RU 38882 whereas dai ly 
topical appli catio ns of cy proterone ace tate result in a dose-de-
pendent decrease in prostate weight (Fig 38) : at the dai ly dose of 
5 m g /cm 2 (25 m g / rat) prostate weight h as decreased by 50%. 
Application of RU 38882 for a lo nger period (3 weeks) leads 
to snmlar results: a daily dose ofO.SO m g / cm 2 has an effect com-
parable to castra tion, a higher dose (5 mg/cm2) is, however, slig htly 
less effecti ve. 
Effect 0 11 th e Castrated Rat: Dail y topical application for 5 d ays 
ofS m g/cm 2 (25 mg/ rat) ofRU 38882 does no r lead to an y in crease 
m the volume density of SER ves icles unlike cy proterone aceta te 
w hich tnggers a sig nifi ca nt increase at the same dose (Table III ). 
Whi le topical application ofR U 38882 does not significantly mod-
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Figure 4. EtTccr of topical application (for 5 days) of RV 38882 and 
cyproterone acetate (Cyp. Ac.) ro intact skin on the androgen receptor 
concentration in the dermis of adult rat. C = Control (intact rat), C.Y = 
castrated rat . 
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Table III. Effect o f Topical Applica tio n o f RU 38882 and Cyprote ro ne A cetate to the Skin of Cas trated Rats 
Dose 
(m g/day/ rat) 
N o. of 
Anim als 
Volume Density 
of SE H. Ves icles 
( x 103 ± SE M) 
AH. Concentration 
(fm ol/m g protein ± SE M) 
Pros tate Weight 
(mg ± SEM) 
Contro l 5 14 ± 2 8 ± 12.1 ± 2.6 
(4 w k cas trated) 
RU 38882 
Cyproterone acetate 
25 
25 
4 
5 
14 ± 1 ( - )'' 
32 + 41' 
5 ± 
0 
10.9 ± 0. 1 (-) 
13.2 ± 2.6 (-) 
Values arc [}1c mea n ::t SE M o f 5 scpar;nc determin atio ns. Similar res ults have bcc11 oblaincd in 3 diffe rent expe rim ents. 
"( -) = Not signi fica ntly di ffe rent from the control group. 
'p < 0.0 1 compared with the control group. 
ify A R con centratio n in the cas tra ted-rat d ermis, cypro tero ne 
ace tate lik e testos tero n e, tri ggers a to tal disappea rance of AR from 
the cy tosol. Under th ese conditions, neithe r RU 38882 no r cy-
pro tero n e acetate m o difies pros tate wei g ht (T able III ). 
DISC USSI O N 
RU 38882 is a new n o n stero ida l antiandrogen [11 , 12.J. Like cy-
pro te ron e ace tate, but to a lesser ex tent , it binds to the androgen 
receptor, and w hen applied to pi call y to the flank-o rga n o f the 
tes tos terone-treated castrated ham ste r , it prevents the m crease m 
flank-o rgan weig ht tri ggered by tes tos tero n e Jl 2 ]. By th e general 
route it is a weak antiandrogen ab o ut 25 t1m es less po tent than 
cyp ro te ron e ace tate. Ho w ever w hen app lied locall y to the skill 
RU 38882 ex hibits a m arked local anti androgem c effec t o n the 
sebaceous g land of the intac t ra t s in ce it is able to d ecrease th e 
volum e density o f SER vesicles in th e diffe rentJ atm g cells to an 
exten t similar to cas tra ti o n . It d o cs n o t ex hibit an y androgcm c 
activity in thi s tes t no r d oes it present an y sys temi c antiandrogenic 
effec t o n the pros tate o r m o dify s ig ni fica ntly serum tes tos te ro ne 
levels . O n the contra ry , cyprote ro ne ace tate w hi ch is a powerful 
antiandrogen b y the general route , under o ur experim ental co n-
ditio ns has pra ctically n o inhibito ry effec t on the hp1d synthesis 
in the se baceous g land w hen applied topica ll y to th e skm of mtact 
rat. Cypro te ro ne ace ta te is kn own to be clini call y ine ffecti ve w hen 
applied to human skin. The lack o f effi cacy of cy pro te ro n e ace tate 
has been a ttribu ted to lack o f pene tratio n o f this compo und through 
the epidermis o r to a m e tab o lic tran sfo rm atio n _11 8] but in o ur 
o pini o n these ex p lanatio ns are no t satisfacto r y s 1n ce even w hen 
applied topi call y to rat skin, cypro te ro n e ace tate IS able to decrease 
pros tate w eig ht. Its la ck o f e ffi cacy could be b ette r ex pl a111ed by 
its pa rtial androgenic activ ity as sh o wn b y 1ts ab1hty to m crease 
b y itself the volume d ens ity o f SER ves icles in the sebaceo us 
g land of the cast ra ted rat afte r to pi ca l applica tio n. . 
It is n ow gen erall y accepted that o ne o f the key events m th e 
develo pment o f the androgenic action of a co mpo und IS ItS In-
te racti o n w ith the androgen recepto r localized in ta rge t ce ll s . The 
complex fo rmed binds to a nu clea r stru cture and triggers a sen es 
o f bi ochemi cal events leadin g to the androgeni c respo nse. Su ch 
a m echanism of actio n has been well-docum ented in th e pros tate, 
and simil ar events h ave been d escribed in animal and human skin 
as well as in the h am ste r sebaceou s g land l19-22]. The subcellular 
localization of th e androgen recepto r depends upo n the horm o nal 
status o f the anim al: suppress ion o f circul atin g androgens by cas-
tratio n lead s to an in creased recovery o f AR in the cy tosol w hile 
topi ca l appli ca tio n of tes tos te ro ne res ults in the disa ppea ran ce o f 
AR fro m cy toso l. T his suggests th at , w hen applied to th e skm , 
i. c., under conditi o ns where it is continu o usly re leased w ith a 
continu al access to free androgen b indin g sites, testos te ro n e fo rm s 
w ith An a complex w hi ch is retain ed in th e nucl eus; A H thus is 
hardl y de tec table in the cytosoli c fr actio n . Applied to pica ll y to 
the skin o f th e cas trated rat , RU 38882 docs n o t m o dify AR 
con centratio n in the cy tosol of th e d ermis, thu s sugges tin g th at 
it ca nno t fo rm w ith AR a complex able to bind to the nucleus. 
Sin ce RU 38882 does not m o dify serum tes tos te ro ne leve ls , th e 
o b se rved in crease in AR con centratio n in the cytosol of intac t rat 
de rmis could thu s be attributed to an inhibition b y RU 38882 of 
th e fo rmatio n and /o r of th e nuclear bindin g o f th e tes tos te ro n e-
An co mplex w hi ch n o rm all y occurs in the presen ce o f the en-
d ogeno u s tes tos te ron e . Thus w hen applied to pi ca ll y RU 38882 
behaves as an antiandrogen o n the skin. O n the contra r y, w h en 
applied to pica lly to th e skin , cypro te ro n e ace ta te b ehaves as a 
partia l agonist. It tri ggers a d ose- rela ted decrease m cy toso iic A~ 
con centra ti o n in r at d ermi s su gges tm g tha t , like testos te ro n e, It 
fo rm s a co mpl ex w ith AR tlut can b e recove red in the nucleu s. 
Cypro teron e ace ta te binds to cytosol AR b y fo rmin g a rapidJy 
d issociatin g co mplex [23) , and it has b een prev io us ly sho wn that 
this kind of compound whi ch behaves as an antagoni st w h en 
g iven as a b o lus o r as repeated injectio n s a t de fin ed time inte rva.ls 
can effec tive ly b ehave as an agonist w hen g iven under condit iOns 
where it has a continuo us access to the recepto r [24] , as w h en 
appli ed to pically to the skin . The pa rti al agoni st acti v ity of cy-
pro te ro n e ace tate could ex plain its la ck o f effi cacy o n th e seba-
ceous gland w hen applied locall y. 
T h e marked local antiandrogcni c acti v ity o f RU 38882 on the 
se baceo us g land was o bser ved o n a s tru c ture (s m oo th e n do-
pl as mi c re ti cu lum) w hi ch see m s direc tl y in vo lved in sebum lipid 
synth es is . Su ch a stru cture IS a lso o bservabl e m the hum an se-
baceo u s g land, and th e volum e d ens ity o f the SER ves icles is 
hi g hl y in creased in hum an sebaceous g lands o f h y pcrseb o rrh eic 
pa tients (d ata n o t shown) . Sin ce, w hen applied locall y to the sk m , 
RU 38882 has n o anti androgeni c ac ti v ity on the pros tate and d oes 
not m o dify circulatin g levels of tes tos terone, it co uld be a u seful 
therapy fo r the local treatm ent o f androg en-dependent "skin dis-
o rde rs" su ch as h ypersebo rrhca, acne, hirsutism , and androgemc 
a lopecia . 
We thank Mrs. C. Couillard, D. C~[!1o, A. 1-1(// III CCtl rt, and C. Vemizeau _{<>r 
th eir cxpn l tedlll iw l assista11a . 
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